Design: a retrospective chart review. Patients were longitudinally followed up for a duration of one year. At the one-year follow-up point, participants completed a comprehensive questionnaire assessing pain intensity using the visual analogue scale (VAS) and also responded to validated surveys including the Pain Catastrophizing Scale (PCS), McGill Pain Questionnaire (MPQ), Pelvic Floor Distress Inventory-20 (PFDI-20), and Female Sexual Function Index (FSFI)

Setting: all patients meeting the eligibility criteria and presenting with myofascial pain at our tertiary care center.

Patients or Participants: consenting females aged 18 and above, proficient in English, diagnosed with MPP, and prescribed BGS. Exclusions encompassed non-consenting patients and pregnant patients

Interventions: a compounded BGS used daily.

Measurements and Main Results: after the start of the BGS, participants exhibited a noteworthy reduction in mean VAS scores, decreasing from a baseline mean of 3 to 1 after one year (p-value <0.0001). A parallel trend was observed in responses to a query about "worst pain". Conversely, inquiries regarding pain intensity failed to reveal a statistically significant change in VAS scores from baseline to the 1-year follow-up. The secondary outcome of PCS demonstrated a significant improvement, with mean scores decreasing from 41.97 at baseline to 33.57 at 1-year follow-up (p-value 0.0009). Conversely, PFDI-20 scores and its subdomains, as well as FSFI scores, did not exhibit statistically significant changes between baseline and 1-year follow-up.

Conclusion: BGS shows promise as an intervention for females suffering from MPP and warrants consideration for patients with this condition. However, further rigorous clinical trials are necessary to establish comprehensive global recommendations for the use of this intervention.